Cheung Kong trials CK Life

Investor presentations begin in Singapore next Tuesday for Li Ka-shing''s latest investment vehicle, Cheung Kong Life Sciences.

A roughly $300 million GEM listing for the biotech arm of the Cheung Kong empire is already starting to whip up a media frenzy and lead manager Salomon Smith Barney is undoubtedly hoping that retail investors are about to shortly follow suit.

All commentators agree that while the 1.3 billion share deal has the outward appearance of a standard IPO, it is in reality little more than a branding exercise for the Li family name, with a highly subjective valuation and almost no growth forecasts. Few doubt that it will be anything other than a great success.

Cheung Kong group managing director HL Kam will explain the benefits of utilizing yeast in the...

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at [email protected], or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at [email protected], or +(852) 2122 5222